GREY:ATBPF - Post by User
Comment by
RalphRalphon Jun 28, 2021 8:46am
164 Views
Post# 33458812
RE:RE:2021 Year End Financial Results
RE:RE:2021 Year End Financial Results Some good for sure, but there are some concerning aspects as well. Note the P3 delay. Also, why has 352 not progressed further? It's perplexing that amidst all other initiatives, they've not been able to advance 352. Before they add more preclinical IP to the pipeline (especially in crowded areas like IBD & Alzheimer's), perhaps they could focus on progressing 340/352. A company with a bunch of preclinical IP is generally not as valuable as a similar company with validated clinical data on 2-3 molecules. IP is only useful if you can move it forward in the clinic.
And still no deal re: Citagenix. The company has definitely taken some good steps, but it would be nice to get some kind of explanation as to why long-discussed goals (Cita, 352 advancement, etc) have not been accomplished.
Forestview wrote: Financials look strong. Good summary. Exciting times ahead.
GameChangerBet wrote: https://www.businesswire.com/news/home/20210628005228/en/Antibe-Therapeutics-Reports-2021-Year-End-Financial-Results-and-Business-Highlights